阿托伐他汀对高脂血症患者补体调节蛋白CD35的影响

目的探讨他汀类调脂药物对高脂血症患者外周血白细胞补体调节蛋白CD35表达的影响及在动脉粥样硬化疾病中的作用。方法选高脂血症患者23例,年龄、性别、体重指数匹配的正常人20例作为对照,用流式细胞术测定外周血白细胞CD35的表达。高脂血症患者使用阿托伐他汀治疗,观察治疗8周后CD35的变化。结果高脂血症患者CD35阳性白细胞、百分率较正常对照组升高(18.40%比12.90%,P<0.05);阿托伐他汀治疗后,CD35阳性白细胞、淋巴细胞、单核细胞、粒细胞平均荧光强度与治疗前比较明显升高(2.02比1.47,3.16比1.60,2.03比1.44,2.05比1.46,P均<0.05),与正常对照组比较亦升高(2.02比1.47,3.16比1.67,2.03比1.52,2.05比1.48,P均<0.05);CD35阳性、淋巴细胞百分率治疗后较治疗前及正常对照组比较均升高(4.93%比3.95%,4.93%比3.35,%,P均<0.05)。结论阿托伐他汀治疗可增加高脂血症患者外周血白细胞补体调节蛋白CD35的表达,提示上调补体调节蛋白的表达可能是他汀类药物延缓动脉粥样硬化进展新的作用机制。

Effects of atorvastatin on complement regulatory protein CD35 in hyperlipidemic patients

Objective To investigate the effects of atorvastatin on the expression of complement regulatory protein CD35 on leukocytes in hyperlipidemic.Methods 23 patients with hyperlipidemia were selected in this study,20 age-,sex-,BMI-matched healthy subjects served as controls.Hyperlipidemic patients were treated with atorvastatin for 8 weeks.Before and after the therapy,the expression of CD35 on leukocytes was examined with flowcytometry.Results The percentage of CD35 positive leukocytes was increased in hyperlipidemic patients compared with healthy controls(18.40% vs 12.90%,P<0.05).After atorvastatin treatment,the mean fluorescences intensity of CD35 positive leukocytes,lymphocytes,monocytes,granulocytes and the percentage of CD35 positive Iymphocytes were markedly increased compared with Pretreatment [(2.02 vs 1.47,3.16 vs 1.60,2.03 vs 1.44,2.05 vs 1.46,P<0.05),(2.02 vs 1.47,3.16 vs 1.67,2.03 vs 1.52,2.05 vs 1.48,P<0.05),(4.93% vs 3.35%,P<0.05)].Conclusion Atorvastatin could increase the expression of complement regulatory protein CD35 in hyperslipidemia,which suggest that upregulating expression of complement regulatory protein might be another anti-athrosclerotic mechanism of statins.